首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Management of heparin-induced thrombocytopenia during continuous renal replacement therapy.
【24h】

Management of heparin-induced thrombocytopenia during continuous renal replacement therapy.

机译:连续性肾脏替代治疗期间肝素诱导的血小板减少的管理。

获取原文
获取原文并翻译 | 示例
       

摘要

Heparin-associated thrombocytopenia occurred in a patient during continuous renal replacement therapy (CRRT), resulting in repeated clotting of the extracorporeal circuit and spontaneous hemorrhage. The peripheral platelet count initially appeared to improve by changing to prostacyclin and dalteparin. However, repeated CRRT circuit clotting recurred, and the platelet count decreased once again. This time the synthetic heparinoid, Orgaran (danaparoid), was used and was associated with successful CRRT and return of the platelet count.
机译:持续性肾脏替代治疗(CRRT)期间,患者发生肝素相关的血小板减少症,导致体外循环反复凝结和自发性出血。通过改变为前列环素和达肝素,外周血小板计数最初似乎有所改善。但是,反复出现CRRT回路反复凝结,血小板计数再次下降。这次使用了合成的类肝素Orgaran(danaparoid),并与成功的CRRT和血小板计数的恢复有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号